Literature DB >> 11800247

Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Andreas Laupacis1.   

Abstract

Mesh：

Year:  2002        PMID： 11800247      PMCID： PMC99226     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  The heartbreak of drug pricing.

Authors:  F Davidoff
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

2.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

3.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

Review 4.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

Review 5.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  L B Russell; M R Gold; J E Siegel; N Daniels; M C Weinstein
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

Review 6.  Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  J E Siegel; M C Weinstein; L B Russell; M R Gold
Journal:  JAMA       Date:  1996 Oct 23-30       Impact factor: 56.272

7.  A study of the quality of life and cost-utility of renal transplantation.

Authors:  A Laupacis; P Keown; N Pus; H Krueger; B Ferguson; C Wong; N Muirhead
Journal:  Kidney Int       Date:  1996-07       Impact factor: 10.612

8.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262

9.  Pharmaceutical price controls and patient welfare.

Authors:  J E Calfee
Journal:  Ann Intern Med       Date:  2001-06-05       Impact factor: 25.391

10.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321
  10 in total
  24 in total

1.  Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures?

Authors:  Amiram Gafni; Stephen Birch
Journal:  CMAJ       Date:  2003-04-01       Impact factor: 8.262

2.  Searching for El Dorado: the impossibility of finding the right rate.

Authors:  Norman Frohlich; Noralou P Roos
Journal:  CMAJ       Date:  2002-10-15       Impact factor: 8.262

3.  Should cost-effectiveness take the blame?

Authors:  Maurice McGregor
Journal:  CMAJ       Date:  2003-06-10       Impact factor: 8.262

4.  Provincial drug benefit programs.

Authors:  Manfred Harth
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

5.  Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

Authors:  Andreas Laupacis; J Michael Paterson; Muhammad Mamdani; Alaa Rostom; Geoffrey M Anderson
Journal:  CMAJ       Date:  2003-11-25       Impact factor: 8.262

6.  "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.

Authors:  Roy West; E Keith Borden; Jean-Paul Collet; Nigel S B Rawson; Robert S Tonks
Journal:  Can J Public Health       Date:  2002 Nov-Dec

7.  NICE methodological guidelines and decision making in the National Health Service in England and Wales.

Authors:  Amiram Gafni; Stephen Birch
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?

Authors:  Suzanne Hill; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

9.  The 'NICE' approach to technology assessment: an economics perspective.

Authors:  Stephen Birch; Amiram Gafni
Journal:  Health Care Manag Sci       Date:  2004-02

10.  Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees.

Authors:  Anders Anell
Journal:  Eur J Health Econ       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.